New combo therapy trial aims to slow advanced breast cancer
NCT ID NCT04448886
Summary
This study is testing whether adding an immunotherapy drug (pembrolizumab) to a targeted cancer drug (sacituzumab govitecan) works better to control advanced breast cancer than the targeted drug alone. It involves about 110 adults with a specific type of breast cancer (HR+/HER2-) that has spread and stopped responding to hormone therapy. Participants are randomly assigned to receive one drug or the combination and are treated as long as it helps them.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
DF/BWCC in Clinical Affiliation with South Shore Hospital
South Weymouth, Massachusetts, 02190, United States
-
DFCI @ Foxborough
Foxborough, Massachusetts, 02035, United States
-
DFCI @ Milford Regional Hospital
Milford, Massachusetts, 01757, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Emory University/Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
University of Chicago Medical Center
Chicago, Illinois, 60637, United States
-
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27599, United States
-
University of Pennsylvania-Abramson Cancer Center
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.